GTx Announces Toremifene 80 mg Phase III ADT Clinical Trial Data to be Presented at the Annual Meeting of the American Urological Association
MEMPHIS, Tenn.--(BUSINESS WIRE)--Apr 22, 2009 - GTx, Inc. (NASDAQ: GTXI) today announced that data from the Phase III clinical trial evaluating toremifene 80 mg for the prevention of fractures in men with prostate cancer on androgen deprivation therapy will be the subject of an oral podium presentation at the 2009 Annual Meeting of the American Urological Association being held in Chicago April 25 - 30.
- Abstract #639 – “Positive fracture reduction trial of toremifene 80 mg in men on ADT demonstrates significant fracture risk in untreated placebo group”
- Sunday, April 26, 2009, 3:30 – 5:30 p.m. Central Time
- McCormick Place Chicago, Room W475 AB
Contact: GTx, Inc.
McDavid Stilwell, 901-523-9700
Director, Corporate Communications & Financial Analysis
Posted: April 2009
